Background
Methods
The cancer genome atlas data access and processing
Demographics and clinicopathologic characteristic analysis
RNA-seq differential gene expression analysis
Pathway enrichment and survival analysis
Results
Patient characteristics
Characteristic | High | Low | P value |
---|---|---|---|
Gender, n | |||
RSC | 156 | 96 | 0.3637 |
Male | 77 | 54 | |
Female | 77 | 42 | |
LSC | 68 | 106 | 0.1231 |
Male | 41 | 51 | |
Female | 27 | 55 | |
REC | 63 | 91 | 0.5118 |
Male | 37 | 48 | |
Female | 26 | 43 | |
MS, n | |||
RSC | 156 | 96 | < 0.0001* |
MSS/MSI-L | 92 | 89 | |
MSI-H | 64 | 7 | |
LSC | 68 | 106 | 0.0771 |
MSS/MSI-L | 64 | 105 | |
MSI-H | 4 | 1 | |
REC | 63 | 91 | 0.0264* |
MSS/MSI-L | 59 | 91 | |
MSI-H | 4 | 0 | |
Age,Mean ± SD | |||
RSC | 70 ± 13.69 | 67 ± 12.95 | 0.2222 |
LSC | 66 ± 11.11 | 64 ± 13.07 | 0.4267 |
REC | 64 ± 10.56 | 65 ± 12.32 | 0.81 |
Pathologic stage, n (%) | |||
RSC | 156 | 96 | 0.0278* |
I | 33(21.2%) | 11(11.5%) | |
II | 73(46.8%) | 38(39.6%) | |
III | 38(24.4%) | 32(33.3%) | |
IV | 12(7.7%) | 15(15.6%) | |
LSC | 68 | 106 | 0.1374 |
I | 12(17.6%) | 17(16.0%) | |
II | 26(38.2%) | 33(31.1%) | |
III | 23(33.8%) | 30(28.3%) | |
IV | 7(10.3%) | 26(24.5%) | |
REC | 63 | 91 | |
I | 10(15.9%) | 20(22.0%) | 0.0279* |
II | 29(46.0%) | 21(23.1%) | |
III | 17(27.0%) | 33(36.3%) | |
IV | 7(11.1%) | 17(18.7%) |
Differential gene expression analysis
Pathway enrichment and survival analysis
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
---|---|---|---|---|
Location | Stages | CLs Status | Gene Symbol | P-value |
Right | Early (I,II) | High | RAET1E | 0.033 |
LILRA1 | 0.031 | |||
CD33 | 0.018 | |||
Low | N/A | |||
Localized (I,II,III) | High | RAET1E | 0.013 | |
LILRA1 | 0.0087 | |||
LILRA4 | 0.042 | |||
CD33 | 0.017 | |||
Low | KLRC1 | 0.027 | ||
Metastasis (IV) | High | MADCAM1 | 0.046 | |
FCGR2B(CD32) | 0.046 | |||
SIGLEC8(CD329) | 0.046 | |||
CLEC4G | 0.046 | |||
Low | CD96 | 0.027 | ||
LILRB1 | 0.015 | |||
ITGB2(CD18) | 0.033 | |||
CD40LG | 0.029 | |||
C3 | 0.018 | |||
SIGLEC9 | 0.0071 | |||
SH2D1A | 0.027 | |||
LAIR1(CD305) | 0.0043 | |||
CD300A | 0.0043 | |||
Left | Early | High | N/A | |
Low | KLRC1 | 0.025 | ||
Localized | High | N/A | ||
Low | N/A | |||
Metastasis | High | N/A | ||
Low | CLEC2B | 0.046 | ||
Rectum | Early | High | N/A | |
Low | CLEC4G | 0.046 | ||
Localized | High | N/A | ||
Low | HCST | 0.019 | ||
FCGR1A(CD64) | 0.039 | |||
CLEC4G | 0.022 | |||
Metastasis | High | N/A | ||
Low | N/A |